Nordic Pharma (Amring Pharmaceuticals)

20 articles about Nordic Pharma (Amring Pharmaceuticals)

• Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), to Present Data on LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting

  4/2/2024

  Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., will be presenting data on LACRIFILL® Canalicular Gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery Annual Meeting in Boston, MA on April 5-8, 2024.

• Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Appoints Renowned Oculoplastic Surgeon, John P. Fezza, MD to Its Medical Advisory Board

  3/14/2024

  Nordic Pharma, Inc., a subsidiary of Nordic Group B.V. announced that eminent oculoplastic surgeon John P. Fezza, MD will serve on its U.S. Medical Advisory Board which includes Eric Donnenfeld, MD, Richard Lindstrom, MD, Vance Thompson, MD, Preeya Gupta, MD, Paul Karpecki, OD, Lisa Nijm, MD, JD, and Selina McGee, OD.

• Amring Pharmaceuticals Inc. Announces Name Change to Nordic Pharma, Inc. Under New Nordic Group, B.V. Ownership

  3/4/2024

  Amring Pharmaceuticals Inc. (“Amring”) announces its name change to Nordic Pharma, Inc. on March 4, 2024, following the change in ownership of the company from SEVER Life Sciences, B.V. to Nordic Group, B.V., a subsidiary of SEVER Life Sciences B.V., which occurred on June 1, 2023.

• Nordic Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Appoints Ophthalmology Innovator, Eric D. Donnenfeld, MD as Medical Advisory Board Chair

  2/26/2024

  Amring Pharmaceuticals Inc. announced that preeminent ophthalmologist Eric D. Donnenfeld, MD will Chair its U.S. Medical Advisory Board which includes Richard Lindstrom, MD, Vance Thompson, MD, Preeya Gupta, MD, Paul Karpecki, OD, Lisa Nijm, MD, JD, and Selina McGee, OD.

• Nordic Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Announces Jai G. Parekh, MD, MBA as Chief Commercial Officer, Eye Care U.S.

  1/15/2024

  Amring Pharmaceuticals Inc., a subsidiary of Nordic Group B.V., announces Jai G. Parekh, MD, MBA as Chief Commercial Officer, Eye Care U.S. Nordic Pharma recently expanded its pharmaceutical expertise in the U.S. by acquiring Visant Medical, Inc., a leader in medical technology innovation in Dry Eye Disease.

• Nordic Pharma Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Completes Acquisition of Visant Medical to Launch Novel Therapy for Dry Eye Disease in the United States

  12/18/2023

  Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announced today the completion of its acquisition of Visant Medical, Inc. (Visant), a leader in medical technology innovation in Dry Eye Disease (DED).

• Amring Pharmaceuticals Inc. Joins End Drug Shortages Alliance

  6/29/2022

  Amring Pharmaceuticals Inc. (Amring), announced today it has joined The End Drug Shortages Alliance (Alliance), a new coalition of diverse stakeholders to address drug shortages in the United States. Alliance provides a forum for key stakeholders to take strategic aim at one of health care’s more pressing and enduring issues, drug shortages that disrupt patient care.

• Amring Pharmaceuticals Inc. Announces the Launch of Timolol Maleate Ophthalmic Solution, USP 0.5%

  6/23/2022

  Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Timolol Maleate Ophthalmic Solution, USP 0.5%, 60 pack of 0.3mL unit dose vials (AT3 rated generic equivalent of Timoptic ® in Ocudose ® ) and has begun commercialization activities.

• Amring Pharmaceuticals Inc. Announces the Approval and Launch of Generic Lamotrigine Orally Disintegrating Tablets (ODT), USP

  2/14/2022

  Amring Pharmaceuticals Inc. announced today that it has received FDA approval for generic Lamotrigine ODT, USP (25mg, 50mg, 100mg and 200mg) available in bottles of 30 tablets (AB rated generic equivalent of Lamictal ® ), and has begun commercialization activities.

• Amzell B.V. and Amring Pharmaceuticals Inc. Attending 2021 American Epilepsy Society Meeting in Chicago

  12/2/2021

  Amzell B.V. (Amzell), a specialist development pharmaceutical company, and Amring Pharmaceuticals Inc. announced today that they will be in attendance at the 2021 American Epilepsy Society (AES) Annual Meeting. The meeting will be held from Dec 3 to Dec 7, 2021, at McCormick Place West in Chicago, IL.

• Amzell, B.V., in Collaboration With Amring Pharmaceuticals Inc. Announce Their Lead Product Has Entered Phase III Clinical Trial in the U.S. for Treatment of Infantile Epileptic Disease

  11/19/2021

  Amzell, B.V. and Amring Pharmaceuticals Inc. announced today that their lead product in the collaboration, AMZ002, has entered Phase III Clinical Trial in the U.S. for treatment of infantile epileptic disease.

• Amring Pharmaceuticals Inc. Licenses LYSTEDA to Pierre Fabre for Mexican Market

  9/29/2021

  Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that on August 23, 2021 it entered into a license agreement with Pierre Fabre Farma de Mexico, S.A. de C.V. (Pierre Fabre), a subsidiary of the Pierre Fabre group which distribute products in over 100 countries around the world.

• Amring Pharmaceuticals Inc. Announces the Approval and Launch of Generic Isoproterenol Hydrochloride Injection USP

  8/5/2021

  Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Isoproterenol Hydrochloride USP, (0.2 mg/mL) available as 1 mL or 5 mL Single-Dose Vials, (AP rated generic equivalent of Isuprel®), and has immediately begun commercialization activity.

• Amring Pharmaceuticals Inc. Enters into License and Development Agreement with Amzell B.V.

  3/12/2021

  Amring Pharmaceuticals Inc. (Amring), a niche brand and generic pharmaceutical company, announced today an agreement with Amzell B.V. (Amzell) that will further strengthen its position in the marketplace with the commercial rights to one of Amzell’s leading clinical-stage programs that will bring a critical and accessible therapy for patients in need.

• Amring Pharmaceuticals Inc. Acquires LYSTEDA®

  12/2/2020

  Amring Pharmaceuticals Inc. (Amring), a generic pharmaceutical company, announced entering into an agreement with Ferring International Center S.A. on December 1, 2020 that will further strengthen its position in the marketplace with the acquisition of the global rights to LYSTEDA® (tranexamic acid),

• Amring Pharmaceuticals Announces the Launch of Two Valued Pharmaceutical Generics

  6/25/2019

  Amring Pharmaceuticals Inc., a generic pharmaceutical and ophthalmic medical device company, announced that it has launched two valued drugs into its generic portfolio and to the U.S. Market

• Amring Pharmaceuticals Announces 2018/19 Launches

  1/4/2019

  Amring Pharmaceuticals Inc. announced today that it launched a generic oncology drug, Arsenic Trioxide Injection in November 2018 and expects to launch four (4) additional generic drugs in 2019.

• The Official US Launch of Biolon OVD (Ophthalmic Viscosurgical Device) for Use in Cataract Surgery

  7/17/2018

  Amring Pharmaceuticals Inc. announced the release of its latest product, Biolon OVD (Ophthalmic Viscosurgical Device).

• Amring Pharma Receives Supplier Horizon Award From Premier Inc.

  7/5/2017

• Amring Pharma Acquired Six ANDAs

  3/9/2017